“Winning the Golden Ticket has had a major impact on Nosis Bio,” says Chad Miller, principal scientist and a co-founder of the company. “More important than the free lab space, the Golden Ticket opened the door to the Foundation, which has an incredible track record of supporting biotech companies to develop revolutionary therapeutics.”
Read post
Gene therapy is usually delivered aboard a harmless virus that can be taken up by cells. However, the immune system may see the introduced gene or the viral carrier as foreign or unfamiliar and react to protect the body, causing an unwanted immune response.
To make delivery safer, Nosis is using AI and deep learning — an AI technique that teaches computers to process data in a way similar to the human brain — to design new molecular carriers to get gene therapy directly into specific lung cells.
Read post
With the Golden Tickets, ARIZ and Catena each win one year of free office and lab space at Bakar Labs and access to BrightEdge’s robust network of resources to develop their cancer therapies. They will be able to access Berkeley campus resources, connect with Bakar Labs' business affiliates, and network with more than 30 fellow tenant companies. The combination of support from Bakar Labs and BrightEdge will, most importantly, allow ARIZ and Catena to bring their technology to patients sooner.
Read post
The three companies win free lab space for a year, with access to our facilities and UC Berkeley ecosystem, and connections to AbbVie experts and industry-scale resources.
Read post
“Our winners are great examples of the companies the Foundation wants to attract – bold, innovative, and unafraid of the challenges ahead. These are the types of early-stage technologies we need to nurture today to bring us closer to a cure for CF tomorrow,” Martin Mense, PhD, senior vice president of drug discovery and director of the CF Foundation Therapeutics Lab.
Read post
“As part of our relentless pursuit of a cure, we are dedicated to investing in early stage science. We know that to make progress toward our bold mission to cure CF, we need to attract bold, like-minded researchers,” said Martin Mense, PhD, senior vice president of drug discovery and director of the Cystic Fibrosis Foundation Therapeutics Lab
Read post
Up to 3 selected companies will win "Golden Tickets" for lab space at Bakar Labs, and access to the extensive resources of the CF Foundation, including scientific experts and advice, lab/research tools and techniques, an extensive patient registry, clinical trial design support, and a Therapeutics Development Network of over 90 clinical trial sites in the US.
Read post